TipRanks
Advertisement
Advertisement

RGEN Stock Latest News

Repligen price target raised to $180 from $145 at Canaccord
The FlyRepligen price target raised to $180 from $145 at Canaccord
4d ago
RGEN
Private Markets: Varda Space, GMI headline week’s startup fundraising
PremiumThe Fly
Private Markets: Varda Space, GMI headline week’s startup fundraising
15d ago
CAT
DHR
Repligen price target raised to $225 from $175 at Barclays
PremiumThe Fly
Repligen price target raised to $225 from $175 at Barclays
16d ago
RGEN
Repligen Completes BioLife Acquisition to Expand Cell Therapies
PremiumCompany Announcements
Repligen Completes BioLife Acquisition to Expand Cell Therapies
17d ago
8K
RGEN
Freshworks to replace BioLife Solutions in S&P 600 at open on 10/8
PremiumThe Fly
Freshworks to replace BioLife Solutions in S&P 600 at open on 10/8
18d ago
BLFS
FRSH
New Grades, Price Targets for the Top-3 Stocks in the Market’s Hottest Sector
PremiumMarket NewsNew Grades, Price Targets for the Top-3 Stocks in the Market’s Hottest Sector
24d ago
IBB
TEM
Repligen Buy Rating Reiterated as Analyst Sees Medium-Term Growth Catalysts; Price Target Maintained at $225
Premium
Ratings
Repligen Buy Rating Reiterated as Analyst Sees Medium-Term Growth Catalysts; Price Target Maintained at $225
24d ago
RGEN
Repligen announces long-serving director Karen Dawes’ retirement
Premium
Company Announcements
Repligen announces long-serving director Karen Dawes’ retirement
1M ago
8K
RGEN
Repligen assumed with a Buy at UBS
PremiumThe Fly
Repligen assumed with a Buy at UBS
1M ago
RGEN
Repligen clears antitrust hurdle in BioLife Solutions acquisition
PremiumCompany Announcements
Repligen clears antitrust hurdle in BioLife Solutions acquisition
1M ago
8K
RGEN
Stifel sees Moderna data as positive for Repligen, Maravai
PremiumThe Fly
Stifel sees Moderna data as positive for Repligen, Maravai
2M ago
MRNA
MRVI
Wells sees Repligen among key beneficiaries of Moderna’s cancer vaccine data
PremiumThe Fly
Wells sees Repligen among key beneficiaries of Moderna’s cancer vaccine data
2M ago
DHR
MRK
Repligen–BioLife Deal: Market, Integration and Regulatory Risks Threaten Growth Outlook and Shareholder Returns
PremiumCompany AnnouncementsRepligen–BioLife Deal: Market, Integration and Regulatory Risks Threaten Growth Outlook and Shareholder Returns
3M ago
RGEN
Repligen’s Operational Momentum Offset by Full Valuation; Kyle Mikson CFA Reiterates Hold with Unchanged $145 Price Target
Premium
Ratings
Repligen’s Operational Momentum Offset by Full Valuation; Kyle Mikson CFA Reiterates Hold with Unchanged $145 Price Target
3M ago
RGEN
Repligen Stock (RGEN) Rises After Investors Wowed By ‘Market Leading’ Q2 Figures
Premium
Market News
Repligen Stock (RGEN) Rises After Investors Wowed By ‘Market Leading’ Q2 Figures
3M ago
RGEN
Repligen price target raised to $175 from $165 at JPMorgan
PremiumThe Fly
Repligen price target raised to $175 from $165 at JPMorgan
3M ago
RGEN
Repligen rises 15.4%
PremiumThe Fly
Repligen rises 15.4%
3M ago
RGEN
Repligen Earns Buy Rating on Strong Q2 Beat, Raised Guidance, and Broad-Based Demand Strength
PremiumRatings
Repligen Earns Buy Rating on Strong Q2 Beat, Raised Guidance, and Broad-Based Demand Strength
3M ago
RGEN
Repligen rises 16.2%
PremiumThe Fly
Repligen rises 16.2%
3M ago
RGEN
Repligen reports Q2 adjusted EPS 54c, consensus 45c
PremiumThe FlyRepligen reports Q2 adjusted EPS 54c, consensus 45c
3M ago
RGEN
Repligen raises FY26 EPS view to $2.03-$2.09 from $1.97-$2.05, consensus $2.00
Premium
The Fly
Repligen raises FY26 EPS view to $2.03-$2.09 from $1.97-$2.05, consensus $2.00
3M ago
RGEN
RGEN Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
RGEN Upcoming Earnings Report: What to Expect?
3M ago
RGEN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >